ストックスクリーナーアプリを入手
13.93
1.47%
0.2163
前日終値:
$13.71
開ける：
$13.9
24時間の取引高:
83,183
Relative Volume:
0.05
時価総額：
$4.44B
収益：
$3.05B
当期純損益:
$181.32M
株価収益率:
37.27
EPS:
0.3737
ネットキャッシュフロー:
$225.64M
1週間 パフォーマンス:
+9.97%
1か月 パフォーマンス:
+5.39%
6か月 パフォーマンス:
+16.21%
1年 パフォーマンス:
+82.80%
1日の値動き範囲:
$13.79
$14.03
1週間の範囲:
$12.49
$14.03
52週間の値動き範囲:
$7.53
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.93 | 4.37B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
15.70 | 49.73B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.25B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.16 | 38.73B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.12 | 33.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
550.11 | 23.12B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | UBS | Buy |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-02-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution - Pharmacy Practice News
Why Amneal (AMRX) stock is trading up today - MSN
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data - Sahm
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations - Yahoo Finance
Amneal reports interim data on Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa
Amneal reports interim data for Parkinson’s drug CREXONT By Investing.com - Investing.com South Africa
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution - The Globe and Mail
Amneal reports interim data on Parkinson’s drug CREXONT - Investing.com UK
Amneal reports interim data for Parkinson’s drug CREXONT - Investing.com
Amneal Pharmaceuticals Reports Positive Interim Data from Phase 4 ELEVATE-PD Study Demonstrating Benefits of CREXONT in Parkinson's Disease Patients - Quiver Quantitative
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease - The Manila Times
Parkinson’s study: CREXONT adds over 3 hours of daily 'Good On' time - Stock Titan
Amneal Pharmaceuticals Says US FDA Approves Romidepsin Injection Solution - Moomoo
AMRX News | AMNEAL PHARMACEUTICALS INC (NASDAQ:AMRX) - ChartMill
Amneal Stock Up on FDA Approval of Romidepsin Injection for Lymphoma PatientsNews and Statistics - IndexBox
Why Amneal (AMRX) Stock Is Trading Up Today - Yahoo Finance UK
Amneal Pharmaceuticals Inc (AMRX) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 70/100 - GuruFocus
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution - Proactive financial news
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.
Amneal Pharmaceuticals Advances After Securing FDA Clearance for Cancer Treatment (AMRX) - Yahoo Finance
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock gains on FDA approval for cancer drug - Investing.com
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now? - Yahoo! Finance Canada
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times
Amneal CEO to present at Goldman Sachs 2026 Global Healthcare Conference in June - Pluang
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Strength And Long Term Gains - Sahm
Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now? - The Globe and Mail
Amneal rated buy in new research coverage at UBS as growth pipeline expands - MSN
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - MSN
Is Amneal Pharmaceuticals (AMRX) Poised for Growth After a Strong Q1 2026 - Kavout
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- G - GuruFocus
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.6% Gain -- GF Value $7.57 vs Price $12.21 - GuruFocus
Stronger Q1 Profitability And Reaffirmed Outlook Could Be A Game Changer For Amneal (AMRX) - simplywall.st
Amneal Pharmaceuticals Is Maintained at Overweight by Barclays - Moomoo
Amneal Shareholders Back Board, Pay and Auditor at Meeting - TipRanks
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
0.19%
0.08%
大文字化:
|
ボリューム (24 時間):